Company news
Apimeds Pharmaceuticals Us, Inc. (AMEX:APUS) news
Apimeds Pharmaceuticals Us, Inc. news releases on 6ix. Latest, Sep 14, 2026: D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc.…
Press releases & updates
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering
September 13, 2026
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October
July 28, 2026
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
May 5, 2026
Apimeds Pharmaceuticals US : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
May 4, 2026
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
March 24, 2026
Apimeds Pharmaceuticals and Lokahi Therapeutics Announce FDA Type C Meeting Scheduled for LT-100
February 12, 2026
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
February 11, 2026
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
December 10, 2025
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
December 1, 2025
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
November 10, 2025
Apimeds Pharmaceuticals says "I love my Ducks" with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
October 14, 2025
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
September 15, 2025
Apimeds Pharmaceuticals Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non Opioid Pain Program
September 12, 2025
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
September 11, 2025
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
August 25, 2025
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
July 15, 2025
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
May 12, 2025
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
May 8, 2025